Konakion (Phytomenadione)

Konakion acts on the coagulation pathway to correct vitamin K‑dependent clotting factor deficiencies.

• Vitamin K deficiency bleeding: restores functional clotting factors to prevent or treat bleeding episodes.
• Newborn hemorrhage prophylaxis: provides essential vitamin K to newborns to reduce risk of early bleeding.
• Warfarin reversal: rapidly counteracts excessive anticoagulation caused by oral vitamin K antagonists.

• Phytomenadione serves as a cofactor for the gamma‑carboxylation of glutamic acid residues on clotting factors II, VII, IX and X in the liver. This enzymatic modification enables the factors to bind calcium ions, a prerequisite for assembling the coagulation complex and generating thrombin, thereby restoring normal hemostasis.

Adverse reactions may occur following administration of Konakion.

Common Side Effects

• Injection site pain or erythema
• Transient fever or chills
• Nausea or mild vomiting
• Headache or dizziness
• Mild hypotension

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction
• Acute hypotension leading to shock
• Thromboembolic events such as deep‑vein thrombosis
• Hemolysis or severe hematuria
• Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Konakion should be used with careful clinical assessment and monitoring.

• Assess bleeding risk: evaluate coagulation status before administration.
• Monitor INR: check clotting parameters after dosing to guide further therapy.
• Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
• Use caution in neonates: follow specific neonatal dosing guidelines.
• Pregnancy and lactation: weigh potential benefits against risks and consult a specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Konakion may interact with several anticoagulant and medication classes.

Major Interactions (Avoid)

• Warfarin: antagonizes anticoagulant effect, may require dose adjustment.
• Acenocoumarol: similar antagonism, can lead to loss of anticoagulation.
• Broad‑spectrum antibiotics: may alter gut vitamin K synthesis, affecting response.

Moderate Interactions (Monitor Closely)

• Heparin: additive anticoagulant effect, monitor coagulation parameters.
• Oral contraceptives: potential increased clotting risk, observe for thrombosis.
• Hepatotoxic chemotherapy agents: may modify clotting factor synthesis, requiring closer INR monitoring.